This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyagi, Y. Articles by Itoh, K. Search for Related Content PubMed PubMed Citation Articles by Miyagi, Y. Articles by Itoh, K.

Induction of Cellular Immune Responses to Tumor Cells and Peptides in Colorectal Cancer Patients by Vaccination with SART3 Peptides¹

Departments of Surgery [Y. M., T. S., T. M., H. I., K. S., H. Y.] and Immunology [N. I., A. Y., K. K., A. M., S. O., K. I.], Kurume University School of Medicine, and Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy [A. Y., M. N., K. I.], Kurume University, 830-0011 Fukuoka, Japan

The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3_109–118 and SART3_315–323) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24⁺ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.

This article has been cited by other articles:

				D. Nagorsen and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069. [Abstract] [Full Text] [PDF]

				T. Ono, M. Harada, A. Yamada, M. Tanaka, Y. Takao, Y. Tanaka, T. Mine, K. Sakamoto, T. Nakashima, and K. Itoh Antitumor Effects of Systemic and Local Immunization with a CTL-Directed Peptide in Combination with a Local Injection of OK-432 Clin. Cancer Res., February 15, 2006; 12(4): 1325 - 1332. [Abstract] [Full Text] [PDF]

				A. Yamada, H. Yano, Y. Takao, T. Ono, T. Matsumoto, and K. Itoh Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an IgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis J. Immunol., January 15, 2006; 176(2): 857 - 863. [Abstract] [Full Text] [PDF]

				N. Yajima, R. Yamanaka, T. Mine, N. Tsuchiya, J. Homma, M. Sano, T. Kuramoto, Y. Obata, N. Komatsu, Y. Arima, et al. Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma Clin. Cancer Res., August 15, 2005; 11(16): 5900 - 5911. [Abstract] [Full Text] [PDF]

				S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results Ann. Onc., June 1, 2005; 16(6): 847 - 862. [Abstract] [Full Text] [PDF]

				S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishihara, and K. Itoh Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer Clin. Cancer Res., September 1, 2004; 10(17): 5828 - 5836. [Abstract] [Full Text] [PDF]

				J. F. Challacombe, A. Rechtsteiner, R. Gottardo, L. M. Rocha, E. P. Browne, T. Shenk, M. R. Altherr, and T. S. Brettin Evaluation of the host transcriptional response to human cytomegalovirus infection Physiol Genomics, June 17, 2004; 18(1): 51 - 62. [Abstract] [Full Text] [PDF]

				M. Harada, R. Gohara, S. Matsueda, A. Muto, T. Oda, Y. Iwamoto, and K. Itoh In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide J. Immunol., February 15, 2004; 172(4): 2659 - 2667. [Abstract] [Full Text] [PDF]

				T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al. Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses Clin. Cancer Res., February 1, 2004; 10(3): 929 - 937. [Abstract] [Full Text] [PDF]

				A. Yamada, K. Kawano, M. Koga, S. Takamori, M. Nakagawa, and K. Itoh Gene and Peptide Analyses of Newly Defined Lung Cancer Antigens Recognized by HLA-A2402-restricted Tumor-specific Cytotoxic T Lymphocytes Cancer Res., June 1, 2003; 63(11): 2829 - 2835. [Abstract] [Full Text] [PDF]

				R. C. Unfer, D. Hellrung, and C. J. Link Jr. Immunity to the {alpha}(1,3)Galactosyl Epitope Provides Protection in Mice Challenged with Colon Cancer Cells Expressing {alpha}(1,3)Galactosyl-transferase: A Novel Suicide Gene for Cancer Gene Therapy Cancer Res., March 1, 2003; 63(5): 987 - 993. [Abstract] [Full Text] [PDF]